Refractory/Recurrent
|
Treatments that so far have
Poor Responses for Ewing's Sarcoma
A
number of chemo agents have been involved in clinical trials for Ewing's
sarcoma and sarcomas in general. This is a partial list of the agents which
have been removed from Ewing's trials due to poor responses.
Gleevec/STI571/Imatinib Mesylate
-
Blocks an abnormal protein, preventing
growth
-
Multi-center Phase 2
Gleevec trial; on or before 3/03,
Ewing's sarcoma was removed from the trial due to lack of response (it
was trialed with 5 patients, responses were 0/5)
-
NIH
description of the trial
-
Open NCI pediatric
Phase 2 trial on Gleevec, open for
Ewing's sarcoma
-
Gleevec side effects
-
2002
abstract of paper about Gleevec and
Ewing's sarcoma cell lines; only tumors that have "constitutively
activated STI571-sensitive tyrosine kinases" responsd to Gleevec
-
2002
reference on 2 Ewing's sarcoma
patients who developed fluid in lungs on Gleevec.
-
2002
abstract stating good cell line
results with Gleevec
-
2001
article about Gleevec and GIST
PS-341/Bortezomib/Velcade
-
Proteasome inhibitor; turns the NF-kB
switch off, killing cells.
-
Was in a trial for sarcomas at MSK by Maki
in 2002, but stopped due to lack of response. (2003 ASCO
abstract which discusses Phase 2 results: 7/11
progression, 2/11 stable,
1/11 mixed; all sarcomas, no Ewing's.)
There seems to be a Phase 2 open now for Ewing's (description)
with Maki as the PI.
-
PS-341 for multiple myeloma
-
2003
abstract discussing toxicity.
-
2002
abstract stating that proteasome
inhibition induces cell death, and it well tolerated.
-
2003
abstract discussing multiple
myeloma success, and stating that perhaps proteasome inhibitors may help
with refractory tumors.
Vaccines and Interleukin-2
|
